671 related articles for article (PubMed ID: 9726240)
1. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.
Ishizuka T; Itaya S; Wada H; Ishizawa M; Kimura M; Kajita K; Kanoh Y; Miura A; Muto N; Yasuda K
Diabetes; 1998 Sep; 47(9):1494-500. PubMed ID: 9726240
[TBL] [Abstract][Full Text] [Related]
2. Formation of PI 3-kinase products in platelets by thrombin, but not collagen, is dependent on synergistic autocrine stimulation, particularly through secreted ADP.
Selheim F; Idsøe R; Fukami MH; Holmsen H; Vassbotn FS
Biochem Biophys Res Commun; 1999 Oct; 263(3):780-5. PubMed ID: 10512757
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinases and phosphoinositide metabolism in thrombin-stimulated human platelets.
Guinebault C; Payrastre B; Sultan C; Mauco G; Breton M; Levy-Toledano S; Plantavid M; Chap H
Biochem J; 1993 Jun; 292 ( Pt 3)(Pt 3):851-6. PubMed ID: 8391259
[TBL] [Abstract][Full Text] [Related]
4. Activation of phospholipase C and protein kinase C has little involvement in ADP-induced primary aggregation of human platelets: effects of diacylglycerols, the diacylglycerols, the diacylglycerol kinase inhibitor R59022, staurosporine and okadaic acid.
Packham MA; Livne AA; Ruben DH; Rand ML
Biochem J; 1993 Mar; 290 ( Pt 3)(Pt 3):849-56. PubMed ID: 8384448
[TBL] [Abstract][Full Text] [Related]
5. Activation of phospholipase D in human platelets by collagen and thrombin and its relationship to platelet aggregation.
Chiang TM
Biochim Biophys Acta; 1994 Oct; 1224(1):147-55. PubMed ID: 7948037
[TBL] [Abstract][Full Text] [Related]
6. Endothelium-derived relaxing factor inhibits thrombin-induced platelet aggregation by inhibiting platelet phospholipase C.
Durante W; Kroll MH; Vanhoutte PM; Schafer AI
Blood; 1992 Jan; 79(1):110-6. PubMed ID: 1309423
[TBL] [Abstract][Full Text] [Related]
7. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.
Yamazaki H; Suzuki M; Tane K; Shimada N; Nakajima M; Yokoi T
Xenobiotica; 2000 Jan; 30(1):61-70. PubMed ID: 10659951
[TBL] [Abstract][Full Text] [Related]
8. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells.
Okura T; Nakamura M; Takata Y; Watanabe S; Kitami Y; Hiwada K
Eur J Pharmacol; 2000 Nov; 407(3):227-35. PubMed ID: 11068018
[TBL] [Abstract][Full Text] [Related]
9. Translocation-independent activation of protein kinase C by platelet-activating factor, thrombin and prostacyclin. Lack of correlation with polyphosphoinositide hydrolysis in rabbit platelets.
Salari H; Duronio V; Howard S; Demos M; Pelech SL
Biochem J; 1990 May; 267(3):689-96. PubMed ID: 2160234
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of the diacylglycerol kinase inhibitor R59022 on thrombin versus collagen-induced human platelet secretion.
Joseph S; Krishnamurthi S; Kakkar VV
Biochim Biophys Acta; 1988 Apr; 969(1):9-17. PubMed ID: 2832002
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone has a reducing effect on thromboxane production.
Hishinuma T; Yamazaki T; Mizugaki M
Prostaglandins Other Lipid Mediat; 2000 Jul; 62(2):135-43. PubMed ID: 10938407
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol turnover in platelet activation; calcium mobilization and protein phosphorylation.
Kaibuchi K; Sano K; Hoshijima M; Takai Y; Nishizuka Y
Cell Calcium; 1982 Oct; 3(4-5):323-35. PubMed ID: 6218878
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes.
Meyer MM; Levin K; Grimmsmann T; Perwitz N; Eirich A; Beck-Nielsen H; Klein HH
Diabetes; 2002 Sep; 51(9):2691-7. PubMed ID: 12196460
[TBL] [Abstract][Full Text] [Related]
14. Effects of nitroblue tetrazolium and vitamin E on platelet ultrastructure, aggregation, and secretion.
White JG; Rao GH; Gerrard JM
Am J Pathol; 1977 Aug; 88(2):387-402. PubMed ID: 879276
[TBL] [Abstract][Full Text] [Related]
15. Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro.
Gralinski MR; Rowse PE; Breider MA
J Cardiovasc Pharmacol; 1998 Jun; 31(6):909-13. PubMed ID: 9641476
[TBL] [Abstract][Full Text] [Related]
16. High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets.
Puri RN; Zhou F; Hu CJ; Colman RF; Colman RW
Blood; 1991 Feb; 77(3):500-7. PubMed ID: 1846761
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts.
Kellerer M; Kroder G; Tippmer S; Berti L; Kiehn R; Mosthaf L; Häring H
Diabetes; 1994 Mar; 43(3):447-53. PubMed ID: 7508875
[TBL] [Abstract][Full Text] [Related]
18. Diacylglycerol overcomes aspirin inhibition of platelets: evidence for a necessary role for diacylglycerol accumulation in platelet activation.
Werner MH; Senzel L; Bielawska A; Khan W; Hannun YA
Mol Pharmacol; 1991 Apr; 39(4):547-56. PubMed ID: 2017154
[TBL] [Abstract][Full Text] [Related]
19. Thrombin-induced human platelet aggregation is inhibited by protein-tyrosine kinase inhibitors, ST638 and genistein.
Asahi M; Yanagi S; Ohta S; Inazu T; Sakai K; Takeuchi F; Taniguchi T; Yamamura H
FEBS Lett; 1992 Aug; 309(1):10-4. PubMed ID: 1511739
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells.
Asano M; Nakajima T; Iwasawa K; Morita T; Nakamura F; Imuta H; Chisaki K; Yamada N; Omata M; Okuda Y
Br J Pharmacol; 1999 Oct; 128(3):673-83. PubMed ID: 10516648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
